Floatz logo

Peg-L-Asparaginase

Refractory T-Cell Lymphoma

Dana-Farber Cancer InstituteEarly Phase 1Dormant
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Refractory T-Cell Lymphoma cohort.

Asset / SponsorPhaseRating
Duvelisib
The First Affiliated Hospital of Xiamen University
Phase 2CCC
DARATUMUMAB
Fondazione Italiana Linfomi - ETS
Phase 2CCC

Same molecule, other indications

Peg-L-Asparaginase is also rated in:

acute lymphoblastic leukemiaDormant
CCC
Indicative ·
55 / 100
View asset →
mixed phenotype acute leukemiaDormant
CCC
Indicative ·
48 / 100
View asset →
acute myeloid leukemiaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →